Company intelligence / Profile preview

Translational Research In Oncology

Edmonton, Alberta, Canada

Ownership: Private
Employees: ~228
Development stage: Other

Overview

TRIO has enabled four major oncology clinical trials that led to new approved drugs/regimens changing standard of care in breast cancer, including docetaxel (BCIRG001), trastuzumab (BCIRG006), palbociclib (TRIO018/TRIO022), talazoparib (TRIO023), and ribociclib (NATALEE); these trials supported pivotal regulatory filings

Therapeutic areas: Oncology
Modalities: Small moleculeMonoclonal antibodyPARP inhibitorCDK4/6 inhibitor
Industry: Academic Hospital/University/Research

Partnerships

eClinical Solutions (clinical data platform)various biopharma sponsors for registration-enabling and pivotal trials

Beyond the preview

Go deeper on Translational Research In Oncology.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Translational Research In Oncology.

Explore the full profile